CPC C07K 14/005 (2013.01) [A61K 39/12 (2013.01); C12N 7/00 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/575 (2013.01); C12N 2770/36122 (2013.01); C12N 2770/36123 (2013.01); C12N 2770/36134 (2013.01); C12N 2770/36151 (2013.01)] | 12 Claims |
1. An immunogenic composition, comprising:
(A) a first virus-like particle (VLP) comprising at least one altered viral protein selected from the group consisting of:
an Eastern equine encephalitis virus (EEEV) E2 protein comprising one or more alterations, relative to the wild-type amino acid sequence, at one or more amino acid locations corresponding to one or more amino acid locations selected from the group consisting of amino acid 170, amino acid 200, amino acid 233, amino acid 234, amino acid 251, and amino acid 256 of Chikungunya virus (CHIKV) E2 protein; and
an EEEV capsid protein comprising one or more alterations, relative to the wild-type amino acid sequence, at a charged amino acid residue in the Nuclear Localization Signal (NLS); and
wherein the at least one altered viral protein is capable of self-assembling into a VLP; and, wherein the one or more alterations enhance VLP production;
(B) a second VLP comprising at least one altered viral protein selected from the group consisting of:
an Western equine encephalitis virus (WEEV) E2 protein comprising one or more alterations, relative to the wild-type amino acid sequence, at one or more amino acid locations corresponding to one or more amino acid locations selected from the group consisting of amino acid 170, amino acid 200, amino acid 233, amino acid 234, amino acid 251, and amino acid 256 of CHIKV E2 protein; and
an EEEV capsid protein comprising one or more alterations, relative to the wild-type amino acid sequence, at a charged amino acid residue in the NLS;
wherein the at least one altered viral protein is capable of self-assembling into a VLP; and, wherein the one or more alterations enhance VLP production; and
(C) a third VLP comprising at least one altered viral protein selected from the group consisting of:
an Venezuelan equine encephalitis virus (VEEV) E2 protein comprising one or more alterations, relative to the wild-type amino acid sequence, at one or more amino acid locations corresponding to one or more amino acid locations selected from the group consisting of amino acid 170, amino acid 200, amino acid 233, amino acid 234, amino acid 251, and amino acid 256 of CHIKV E2 protein; and
an EEEV capsid protein comprising one or more alterations, relative to the wild-type amino acid sequence, at a charged amino acid residue in the NLS; and
wherein the at least one altered viral protein is capable of self-assembling into a VLP; and, wherein the one or more alterations enhance VLP production.
|